Cancer Immunotherapy
Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).
Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.
-
RO5323441
0 ImagesCat. No.: HY-P991430Synonyms: TB-403RO5323441 (TB-403) is a human IgG1 monoclonal antibody (mAb) targeting PlGF. RO5323441 inhibits the binding of human PlGF-1 or PlGF-2 to VEGFR-1 (IC50 values are 0.1 and 0.2 nM, respectively). RO5323441 blocks PlGF-induced VEGFR-1 phosphorylation in Flt-1-transfected HEK293 cells. RO5323441 has antitumor activity.
-
1-Oleoyl-2-acetylglycerol
0 ImagesCat. No.: HY-W724097CAS No.: 84746-00-91-Oleoyl-2-acetylglycerol is a membrane-permeable diacylglycerol analog and PKC activator. 1-Oleoyl-2-acetylglycerol activates TRPC3 channels. 1-Oleoyl-2-acetylglycerol attenuates D609 (HY-70072)-induced Apoptosis. 1-Oleoyl-2-acetylglycerol effectively stimulates insulin secretion. 1-Oleoyl-2-acetylglycerol can be used in research on monocytic leukemia.
-
Coelenterazine TFA
0 ImagesCat. No.: HY-18743APurity: 99.14%Coelenterazine TFA is a luminescent enzyme substrate for apoaequorin and Renilla luciferase. Renilla luciferase and substrate Coelenterazine TFA has been used as the bioluminescence donor in bioluminescence resonance energy transfer (BRET) to detect protein-protein interactions. Coelenterazine TFA is a superoxide anion-sensitive chemiluminescent probe and it can also be used in chemiluminescent detection of peroxynitrite (Ex/Em = 429/466 nm).
-
Glidobactin G
0 ImagesCat. No.: HY-N14023CAS No.: 119259-71-1Glidobactin G is an anti-tumor antibiotic. Glidobactin G has the activity against pathogenic fungi and yeast. Glidobactin G also extends the survival of mice inoculated with leukemia P388 cells.
-
Aranciamycin
0 ImagesCat. No.: HY-123886CAS No.: 72389-06-1Aranciamycin (Compound 1) is an anthracycline antibiotic with collagenase inhibitory activity (IC503.7*10-7M). Aranciamycin can be used to inhibit DNA synthesis in tumor cells .
-
Pirarubicin Hydrochloride (Standard)
0 ImagesCat. No.: HY-13725ARCAS No.: 95343-20-7Synonyms: THP Hydrochloride (Standard)Pirarubicin (Hydrochloride) (Standard) is the analytical standard of Pirarubicin (Hydrochloride). This product is intended for research and analytical applications. Pirarubicin Hydrochloride is an anthracycline antibiotics, acts as a topoisomerase II inhibitor, and is a widely used for treatment of various cancers, in particular, solid tumors.
-
Phototherapeutic agent-1
0 ImagesCat. No.: HY-D1468CAS No.: 2555045-67-3Phototherapeutic agent-1 is a multi-modal light diagnosis agent with aggregation-induced emission properties. have certain Phototherapeutic agent-1 has certain reactive oxygen species (ROS) generation capacity in illumination condition. Phototherapeutic agent-1 can effectively kill cancer cells and tumor tissue.
-
(rac)-Etodolac-d3
0 ImagesCat. No.: HY-76251S1CAS No.: 1276197-46-6(rac)-Etodolac-d3 is a labelled racemic Etodolac. Etodolac (AY-24236) is a non-steroidal anti-inflammatory compound that is a non-selective inhibitor of COX (IC50=53.5 nM)
-
KKI-5
0 ImagesCat. No.: HY-P0237CAS No.: 97145-43-2KKI-5 is a specific inhibitor of tissue kallikrein. KKI-5 can attenuate breast cancer cell invasion.
